Cost effectiveness of pharmacotherapies in early Parkinson's disease

CNS Drugs

Volumn 22, Issue 10, 2008, Pages 841-860

  Eggert, Karla M ^a   Reese, Jens P ^a   Oertel, Wolfgang H ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antiparkinsonians, therapeutic use; Bromocriptine, therapeutic use; Cabergoline, therapeutic use; Cost effectiveness; Parkinson's disease, treatment; Pergolide, therapeutic use; Pramipexole, therapeutic use; Quality of life

Indexed keywords

ALTEPLASE; AMANTADINE; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HUMAN; LONG TERM CARE; MONOTHERAPY; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; COST-BENEFIT ANALYSIS; HUMANS; PARKINSON DISEASE;

EID: 51749119244     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822100-00005     Document Type: Review

References (92)

1. Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16 (3): 278-82
2. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986; 19 (4): 365-72
3. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994; 17 Suppl. 2: S32-44
4. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section, part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13 (11): 1170-85
5. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10): 1013-38
6. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005; 12: 956-63
7. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49 (3): 298-303
8. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61 (7): 1044-53
9. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006; 21 (3): 343-53
10. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006; 21 (11): 1844-50
11. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. New Engl J Med 2007; 356 (1): 29-38
12. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1989; 321 (20): 1364-71
13. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002; 59 (12): 1937-43
14. Marras C, Lang AE. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Expert Rev Neurother 2004; 4 (6): 985-93
15. Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002; 17 (5): 867-76
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17 (5): 427-42
17. Mitchell SL, Harper DW, Lau A, et al. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 2000; 19 (2): 100-8
18. Reynolds Jr NC, Montgomery GK. Factor analysis of Parkinson's impairment: an evaluation of the final common pathway. Arch Neurol 1987; 44 (10): 1013-6
19. Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69 (1): 67-73
20. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997; 26 (5): 353-7
21. Welsh M, McDermott MP, Holloway RG, et al. Development and testing of the Parkinson's disease quality of life scale. Mov Disord 2003; 18 (6): 637-45
22. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19 (9): 1020-8
23. Fahn RE, Committee UD. Unified Parkinson's Disease Rating Scale. In: Fahn S, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park (NJ): Macmillan Healthcare Information, 1987: 153-63
24. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson ML, editors. Third symposium on Parkinson's disease. Edinburgh: E&S Livingstone, 1969: 152-7
25. Goetz CG, LeWitt PA, Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 2003; 18 (12): 1455-8
26. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22 (1): 41-7
27. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. New Engl J Med 2006; 355 (9): 896-908
28. Behari M, Srivastava AK, Pandey RM. Quality of life in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11 (4): 221-6
29. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15 (6): 1112-8
30. Reuther M, Spottke EA, Klotsche J, et al. Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007; 13 (2): 108-14
31. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17 (1): 60-7
32. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007; 22 (11): 1528-37
33. Torrance GW. Utility measurement in healthcare: the things I never got to. PharmacoEconomics 2006; 24 (11): 1069-78
34. Den Oudsten BL, Van Heck GL, De Vries J. The suitability of patient-based measures in the field of Parkinson's disease: a systematic review. Mov Disord 2007; 22 (10): 1390-401
35. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006; 23 (9): 693-721
36. Hagell P, Whalley D, McKenna SP, et al. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord 2003; 18 (7): 773-83
37. Martinez-Martin P, Grandas F, Linazasoro G, et al. Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. Neurologia 1999; 14 (7): 338-43
38. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305 (6846): 160-4
39. Longstreth Jr WT, Nelson L, Linde M, et al. Utility of the sickness impact profile in Parkinson's disease. J Geriatr Psychiatry Neurol 1992; 5 (3): 142-8
40. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 2002; 59 (1): 103-8
41. EuroQol: a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16 (3): 199-208
42. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states: results from a six-country study. Eur J Health Econ 2003; 4: 222-31
43. Brazier JE, Walters SJ, Nicholl JP, et al. Using the SF-36 and EuroQol on an elderly population. Qual Life Res 1996; 5 (2): 195-204
44. Beck A, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-7
45. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992; 21 (3): 249-79
46. Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007; 27 (3): 327-34
47. Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Med Decis Making 2004; 24 (5): 472-85
48. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 Suppl. 1: S10-4
49. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4 (3): 241-8
50. de Boer AG, Wijker W, Speelman JD, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996; 61 (1): 70-4
51. Schulzer M, Mak E, Calne SM. The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease. Parkinsonism Relat Disord 2003; 9 (5): 291-4
52. Tan LC, Luo N, Nazri M, et al. Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson's disease patients in Singapore. Parkinsonism Relat Disord 2004; 10 (8): 493-9
53. Hely M, Chey T, Wilson A, et al. Reliability of the Columbia Scale for assessing signs of Parkinson's disease. Mov Disord 1993; 8: 466-72
54. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19 (7): 729-52
55. Lindgren P. Economic evidence in Parkinson's disease: a review. Eur J Health Econ 2004; 5 Suppl. 1: S63-6
56. Lindgren P, von Campenhausen S, Spottke E, et al. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; 12 Suppl. 1: 68-73
57. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 68-93
58. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14 (3): 299-312
59. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16 (1): 59-69
60. Hagell P, Nordling S, Reimer J, et al. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002; 17 (6): 1213-20
61. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003; 18 (10): 1139-45
62. Keränen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9 (3): 163-8
63. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005; 23 (8): 817-36
64. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005; 20 (11): 1449-54
65. Dengler I, Leukel N, Meuser T, et al. Prospective study of the direct and indirect costs of idiopathic Parkinson's disease. Der Nervenarzt 2006; 77 (10): 1204-9
66. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
67. Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson's disease [abstract]. Ann Neurology 1988; 24 (1): 153
68. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 94-112
69. Tranmer JE, Guerriere DN, Ungar WJ, et al. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 2005; 23 (5): 449-59
70. Schöffski O, von der Schulenburg J-M. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation. Revidierte Fassung des Hannoveraner Konsens. In: Schöffski O, von der Schulenburg J-M, editors. Gesundheitsökonomische Evaluationen. Berlin: Springer, 2007: 479-84
71. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000; 15 (3): 439-45
72. Coyle D, Barbeau M, Guttman M, et al. The economic evaluation of pharmacotherapies for Parkinson's disease. Parkinsonism Relat Disord 2003; 9 (5): 301-7
73. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005; 43 (7 Suppl.): 5-14
74. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005; 8 (5): 521-33
75. Glick HA, Polsky DP, Schulman KA. Trial-based economic evaluations: an overview of design and analysis. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 113-40
76. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002; 360 (9334): 711-5
77. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation. Report of the ISPOR Task Force on Good Research Practices: modeling studies. Value Health 2003; 6 (1): 9-17
78. Siebert U, Bornschein B, Walbert T, et al. Systematic assessment of decision models in Parkinson's disease. Value Health 2004; 7 (5): 610-26
79. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043-53
80. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 172-214
81. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3 (2): 95-104
82. O'Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23 (6): 529-36
83. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002; 11 (6): 455-68
84. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998; 14 (5): 541-57
85. Noyes K, Dick AW, Holloway RG. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness. Pharmacoeconomics 2005; 23 (12): 1257-70
86. Lindgren P, Jonsson B, Duchane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. Eur J Health Econ 2003; 4 (1): 37-42
87. Smala AM, Spottke EA, Machat O, et al. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 2003; 18 (8): 898-905
88. Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001; 4 (4): 308-15
89. Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001; 19 (8): 875-86
90. Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 2003; 21 (2): 115-27
91. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23-30
92. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New Engl J Med 2000; 342: 1484-91